A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer

Trial Profile

A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Early breast cancer; Male breast cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms NeoEribulin; SOLTI NEOERIBULIN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Dec 2015 Results of sub-group analysis (n=92) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 02 Dec 2015 Results will be presented at the San Antonio Breast Cancer Symposium (SABCS), as per Eisai Co Ltd media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top